课题基金 / 基金详情

Mechanisms of lincDUSP Oncogenic Effects in Colon Cancer

Mechanisms of lincDUSP Oncogenic Effects in Colon Cancer
lincDUSP 对结肠癌的致癌作用机制
批准号:
10683922
负责人:
Thomas Louis LaFramboise
金额:
$36.09万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2024-08-31

项目摘要

项目成果

Thomas Louis LaFramboise的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PI: Khalil, Ahmad Technical Abstract: Colon cancer is the second leading cause of cancer-related death in the United States, largely due to frequent treatment failure and recurrence. Recent studies, including work from our laboratory, have demonstrated that regulatory long intergenic non-coding RNAs (lincRNAs) are major players in the process of colon tumorigenesis, and could emerge as novel therapeutic targets. In this proposal, we have identified and functionally characterized a novel lincRNA, referred to as lincDUSP, that exerts an oncogenic effect in colon cancer cells. Knockdown of lincDUSP significantly abrogates the tumor phenotype, including decreased proliferation and colony formation, and increased apoptosis. These studies have also revealed that lincDUSP regulates numerous genes by directly interacting with chromatin, and potentially recruiting protein complexes to specific genomic loci. In aim 1 of this proposal, we will further test the oncogenic function of lincDUSP in vivo using a xenograft model, and also assess the role of lincDUSP in driving colon tumorigenesis using 3D organoids. In aim 2, we will investigate the molecular mechanisms of lincDUSP by assessing its role in gene regulation, and characterize the protein complexes that are required for lincDUSP oncogenic activity. Lastly, we will determine the secondary structure of lincDUSP that facilitates its interaction with DNA and proteins. The completion of the proposed studies could lead to establishing lincDUSP as a novel oncogenic lincRNA with direct impact on colon tumorigenesis, and possibly as a target for therapy.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
缺失5Q产生的分子特征的病理生理和临床意义。
DOI: 10.1016/j.ebiom.2022.104059
发表时间: 2022-06
期刊: EBioMedicine
影响因子: 11.1
作者: [Adema V, Palomo L, Walter W, Mallo M, Hutter S, La Framboise T, Arenillas L, Meggendorfer M, Radivoyevitch T, Xicoy B, Pellagatti A, Haferlach C, Boultwood J, Kern W, Visconte V, Sekeres M, Barnard J, Haferlach T, Solé F, Maciejewski JP]
通讯作者: Maciejewski JP
DOI: 10.1038/s41467-022-28678-x
发表时间: 2022-02-24
期刊: Nature communications
影响因子: 16.6
作者: [Woerner J, Huang Y, Hutter S, Gurnari C, Sánchez JMH, Wang J, Huang Y, Schnabel D, Aaby M, Xu W, Thorat V, Jiang D, Jha BK, Koyuturk M, Maciejewski JP, Haferlach T, LaFramboise T]
通讯作者: LaFramboise T
Integrative Systems Biology Core
  • 批准号:
    10713944
  • 项目类别:
  • 资助金额:
    $32.69万
  • 财政年份:
    2023
  • 负责人:
    Thomas Louis LaFramboise
  • 依托单位:
Integrating Clues from the Somatic Genome in the Search for Rare Germline Cancer Susceptibility Variants
  • 批准号:
    10159876
  • 项目类别:
  • 资助金额:
    $18.82万
  • 财政年份:
    2020
  • 负责人:
    Thomas Louis LaFramboise
  • 依托单位:
Mechanisms of lincDUSP Oncogenic Effects in Colon Cancer
  • 批准号:
    10232150
  • 项目类别:
  • 资助金额:
    $36.09万
  • 财政年份:
    2018
  • 负责人:
    Thomas Louis LaFramboise
  • 依托单位:
Computational Genomic Epidemiology of Cancer (CoGEC) Training Program
  • 批准号:
    10623378
  • 项目类别:
  • 资助金额:
    $29.94万
  • 财政年份:
    2017
  • 负责人:
    Thomas Louis LaFramboise
  • 依托单位:
海外基金